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AbstrAct
Introduction Cachexia is common in malignant 
mesothelioma (MM); half of patients have malnutrition 
and low skeletal muscle mass. Malnourished patients 
have worse quality of life (QoL). Weight loss is strongly 
associated with poor survival. Anamorelin is an oral 
ghrelin receptor agonist that improves appetite, body 
weight and QoL in advanced cancer. The aim of this study 
is to examine the efficacy of anamorelin in improving 
appendicular skeletal muscle mass (ASM) and patient- 
reported outcomes in patients with MM with cachexia.
Methods and analysis A single- centre, phase II, 
randomised, placebo- controlled cross- over pilot study 
with 28- day treatment periods and 3- day washout. 
Forty patients will be randomised. Primary outcome 
is change in ASM relative to height measured by 
dual energy X- ray absorptiometry at end of period 
1. Secondary outcomes include cancer- specific and 
cachexia- related QoL, objective physical activity, 
dietary intake and adverse events. Eligible patients will 
have confirmed MM, Eastern Cooperative Oncology 
Group 0–2, expected survival >3 months and cachexia 
(defined as >5% weight loss in 6 months or body mass 
index <20 kg/m2 with weight loss >2%).
Ethics and dissemination Ethical approval has been 
granted. Results will be reported in peer- reviewed 
publications.
trial registration number Australian New Zealand 
Clinical Trials Registry (U1111-1240-6828).
InTroduCTIon
Malignant pleural mesothelioma (MPM) 
is a rare and universally fatal cancer devel-
oping from the mesothelial monolayer of 
the thoracic and abdominal cavities1 and has 
a median survival of 9–12 months.2 Treat-
ment is palliative, with combination chemo-
therapy providing only a modest improve-
ment in overall survival.3 Australia has one 
of the highest rates of mesothelioma per 
capita worldwide due to asbestos mining and 
use. In 2017, the age- standardised rate of 
mesothelioma in Australia was 2.7/100 000 
population, an increase of 123% since 1982, 
with 779 deaths nationally.4 Pleural mesothe-
lioma accounts for ~95% of all mesothelioma 
cases.5 6
Weight loss, low muscle mass and malnutri-
tion are common in patients with MPM and 
these are associated with poor quality of life 
(QoL), physical functioning and perhaps 
lower survival. A recent study examining 
patients with MPM found that high rates of 
malnutrition (38%) and low skeletal muscle 
mass (54%) were present shortly after diag-
nosis (median 2 months).7 Participants with 
malnutrition had lower QoL (p<0.001), while 
participants with low skeletal muscle mass 
were more inactive compared with those with 
normal muscle mass (p=0.001).7 Addition-
ally, participants with malnutrition and had 
significantly higher levels of the proinflamma-
tory cytokine, interleukin (IL) 6, compared 
with well- nourished participants (median 
11.0 (IQR 4.7–18.8) pg/mL versus median 
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Key messages
 ► Our protocol details the design of a study to exam-
ine the efficacy of anamorelin in improving appen-
dicular skeletal muscle mass and patient- reported 
outcomes in patients with malignant mesothelioma 
with cachexia.
 ► Anorexia is a major symptom in mesothelioma, and 
weight loss and cachexia are common and have 
prognostic importance, as such, management of 
anorexia is key in optimising both quality of life and 
survival.
 ► We believe our study is timely and relevant in a co-
hort of patients of which cachexia remains a promi-
nent issue and that our protocol proposes the use of 
an agent that has been minimally used in the meso-
thelioma population.
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2.6 (2.0–7.9) pg/mL; p=0.002).7 These results suggest 
the presence of systemic inflammation in our malnour-
ished participants with MPM and are indicative of cancer 
cachexia rather than simple malnutrition.
Numerous studies have shown that weight loss may be 
directly related to worse survival in MPM.2 8–10 A post-
mortem study of 318 patients with MPM found that body 
mass index (BMI) was significantly lower where there was 
no identifiable anatomic cause of death.8 The mean BMI 
of this cohort was 19.98 (SD 4.9) and BMI was signifi-
cantly lower in patients with no identified anatomic 
cause of death, compared with those where causes were 
apparent (18.8 (SD 4.3) vs 21.0 (4.7); p=0.034).8 A recent 
prognostic model for MPM was consistent with this 
notion, demonstrating that the presence of weight loss 
at the time of diagnosis of MPM has the strongest asso-
ciation with survival.2 Additionally, post- hoc analyses of 
the Regular Early Specialist Palliative Care Mesothelioma 
(RESPECT- Meso) study also demonstrated that loss of 
appetite was associated with worse survival (HR 2.3 (95% 
CI 1.2 to 4.4, p=0.01)).9 10 Overall, these findings suggest 
any interventions that can potentially reduce weight loss 
or improve appetite associated with advanced cancer 
may positively impact on QoL, physical functioning and, 
perhaps, survival.
Current treatment options for cancer cachexia are very 
limited. Oral corticosteroids and progestins can improve 
appetite and total body weight (TBW) but have no bene-
ficial effect on skeletal muscle mass.11 These drugs pose 
a significant risk of side effects that can impact multiple 
body symptoms.12 Ghrelin receptor agonists have been 
developed as a treatment for cancer cachexia. Ghrelin 
is predominantly produced in the stomach and rapidly 
stimulates appetite leading to increased food intake. 
Ghrelin also triggers other physiological changes such 
as stimulation of gastric emptying and increased skeletal 
muscle, probably from inducing growth hormone secre-
tion and insulin- like growth factor (IGF)-1 release.13
Anamorelin is a ghrelin receptor agonist and in 
advanced cancers it improves TBW, lean body mass (LBM), 
appetite and QoL.14–17 A recent systematic review of the 
effects of anamorelin identified 6 randomised controlled 
trials of 1641 participants.18 These comprised two phase 
III trials in in non- small cell lung cancer (NSCLC) and 
four phase II studies with mixed cancer cohorts. In these 
studies, there is a consistent treatment effect favouring 
anamorelin, with statistically significant improvements in 
TBW, LBM and QoL.18 Since the systematic review, there 
has been a further phase III study trialling anamorelin 
in NSCLC and a phase II study in mixed gastrointes-
tinal cancers (mainly colorectal).19 20 The phase III study 
in NSCLC demonstrated a mean increase in LBM by 
1.38 kg ±0.18 (p<0.001) with associated increases in body 
weight (1.06 kg ±0.2, p<0.0001) and appetite (p=0.0005), 
compared with placebo over a 12- week period.19 The 
participants with gastrointestinal cancer in the phase II 
study demonstrated a similar increase in LBM of 1.89 kg 
±0.36, and increase in appetite.20
The majority of these studies administered anamorelin 
to participants over a 12- week period. In responders, a 
pattern of rapid improvement in appetite and weight 
occurs within the first 3 weeks which progresses to 
sustained benefit for the duration of the studies.15 17 19 20 
Improvement in cachexia- related biomarkers collected 
throughout these studies followed a similar pattern, with 
biomarkers such as IGF-1, IGF3, IGF- binding protein 
3, prealbumin and transthyretin increasing to a peak 
at week 3 or 4, then plateauing or decreasing after this 
point.15 17 19 20
Despite the clear promise as a palliative therapeutic 
agent in both improvement in weight and QoL, anamo-
relin has not had regulatory approval, in part, because 
coprimary outcome measures were not significantly 
improved in the two large, phase III anamorelin in lung 
cancer cachexia (ROMANA) studies.17 The Federal 
Drugs Administration requirement for inclusion of hand 
grip strength as a coprimary outcome measure. These 
studies, with 979 participants, demonstrated a clear statis-
tically significant benefit in LBM favouring anamorelin as 
well as a consistent improvement in appetite and QoL but 
failed the coprimary endpoint on hand grip strength.17 
In our studies, we have found that hand grip strength is 
not sensitive to change in our MPM population in both 
observational and interventional cohorts.21
Anamorelin is well tolerated with no dose- limiting 
toxicities identified to date; the frequency of grade 3 
and 4 toxicities is the same as for patients receiving 
placebo.18 Hyperglycaemia is the most common high- 
grade toxicity but occurs in <1% of participants.17 Mild 
nausea and abnormal liver function tests are the other 
most frequently reported adverse events (AE) in up to 
1:10 patients. There have been concerns in early phase 
clinical studies about cardiovascular toxicity, but this was 
not borne out in later phase studies, with the rates of 
cardiovascular events being similar between anamorelin 
and placebo.17 Two dose levels of anamorelin have been 
examined (50 mg and 100 mg daily), with the 100 mg 
dose considered optimal to improve skeletal muscle mass 
without any increase in AE.
Anamorelin has yet to be examined in patients with 
MPM. The aim of this randomised controlled trial is to 
assess if anamorelin improves muscle mass and QoL in 
patients with MPM as compared with placebo.
MeThods and analysIs
Primary aim
The primary aim of this trial is to examine the efficacy 
of anamorelin in improving appendicular skeletal muscle 
mass (ASM) relative to height in cachectic patients with 
MPM. This will be measured at 28 days by dual- energy 
X- ray absorptiometry (DXA; Hologic Discovery A, 
Hologic, Marlborough, Massachusetts, USA) scan. ASM 
has been chosen as a measure of skeletal muscle mass, as 
it represents approximately 75% of total skeletal muscle 
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box 1 Inclusion and exclusion criteria
Inclusion criteria
 ► Adults (18 years and above)
 ► Histological or cytological confirmation of malignant pleural mesothelioma
 ► Cachexia (defined as >5% weight loss in 6 months or body mass index <20 kg/m2 with weight loss >2%);
 ► Life expectancy >3 months at randomisation,
 ► Eastern Cooperative Oncology Group performance status 0–2,
 ► At least 3 weeks since last received systemic anticancer therapy
Exclusion criteria
 ► Peritoneal disease
 ► Other significant comorbidity or organ dysfunction which may affect outcome measures or safety,
 ► Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
 – History or presence of ventricular tachyarrhythmia
 – Presence of unstable atrial fibrillation (ventricular response >120 beats/min at rest); patients with stable atrial fibrillation are eligible, provided 
they do not meet any of the other cardiac exclusion criteria
 – Corrected QT interval (QTcF) >480 ms on baseline ECG.
 ► Patients with abnormal liver function tests, defined as any of the following:
 – Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)>3 times the upper limit of normal (ULN), or AST or ALT>5 times ULN for 
patients with liver metastases
 – Total bilirubin >1.5× ULN, except for patients with Gilbert’s syndrome who are excluded if total bilirubin >3.0× ULN or direct bilirubin >1.5× ULN
 ► Participation in another study (drug or non- drug study) that may affect outcome measures
 ► Concurrent chemotherapy or radiotherapy (immunotherapy is accepted), including planned chemotherapy or radiotherapy commencing during the 
study period
 ► Concurrent use of appetite stimulants including oral corticosteroids (other than for adrenal replacement), mirtazapine (other than for major depres-
sive disorder), or progesterones
 ► Patients who are receiving treatment with medications, that cannot be discontinued prior to study entry and that are considered to be any of the 
following:
 – known risk for QT prolongation
 – known to be strong inducers or inhibitors of CYP3A4/5
 ► Uncontrolled diabetes mellitus (defined as random blood glucose >11.1 mmol/L and glycated haemoglobin>7.0%)
 ► Significant active gastrointestinal disease that might impair absorption of study treatment
 ► Inability to readily swallow oral tablets or intractable or frequent vomiting
and has shown to correlate well with nutrition and phys-
ical status.7 22
secondary aims
The secondary aims include assessment of ASM at 60 
days and overall changes in weight, objective physical 
activity, physical functioning and dietary intake. Each of 
these measurements will be taken at baseline, 28 days and 
60 days. Cancer- specific and cachexia- related QoL will 
be measured using the Functional Assessment Cancer 
Therapy—Lung (FACT- L)23 and Anorexia Cachexia 
Scale (ACS) instruments at the same time points.24
Objective activity behaviours will be assessed at each 
time point Actigraph GT3X+accelerometer (Acti-
graph, Pensacola, Florida, USA). Participants will be 
instructed to wear the accelerometer on their hip contin-
uously (24 hours/day) for 3 days.7 Dietary intake will be 
measure by a 24 hours recall completed in an interview 
with a dietitian. Physical function will be objectively 
assessed using three different measures: repeated chair 
rise, gait speed and hand- grip strength. These physical 
functioning assessments are in accordance with current 
consensus documents regarding sarcopenia.25 Hand grip 
strength has been included to add applicability to other 
similar studies in malnutrition and sarcopenia, as well 
as to directly compare to previous studies with anamo-
relin.17 26 27
Survival will be measured from the date of randomi-
sation to death from any cause, or censure at end of 
study (12 weeks after last participant randomisation). 
Adverse effects from anamorelin will be actively moni-
tored throughout the course of the study at the face- 
to- face participant visits and during planned telephone 
interactions. Patient preference for the first or second 
study period will also be assessed by a study- specific 
questionnaire.
exploratory aims
Correlative biomarkers of anorexia, cachexia and nutri-
tion will be examined to assess if there is a change in 
response to anamorelin. These include inflammation- 
associated factors in the serum: interferon- gamma, IL-1 
alpha, IL1 beta, IL-10, IL-13, IL-4, IL-6, IL-8, monocyte 
chemoattractant protein-1 and tumour necrosis factor 
alpha. Serum albumin, plasma glycerol, serum leptin, 
ghrelin, transthyretin and serum adiponectin will also be 
measured. The choice of correlative biomarkers is based 
on previous studies of cachexia in mesothelioma.7 28
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Table 1 Study visit schedule
Assessment
Baseline Period 1
Washout/
second 
visit Period 2
Final 
visit
D0 D1
D14 
(±1) D26 D28
D29–31
(±3) D32 (±3)
D46 
(±1) D58 D60
D61 
(±3)
Blood collection 
(biomarker analysis, 
safety blood tests)
X First dose of 
study drug/
placebo for 
period 1
X Final dose of 
study drug/
placebo for 
period 1
X First dose of 
study drug/
placebo for 
period 2
X Final dose of 
study drug/
placebo for 
period 2
X
DXA X   X X
Weight X   X X
ECG X   X X
QoL: FACT- L and ACS X   X X
Accelerometer X*   X* X*
24 hours dietary recall X   X X
Assessment of toxicity X X X X X
*Wear accelerometer.
ACS, Anorexia Cachexia Scale; DXA, dual X- ray absorptiometry; FACT- L, Functional Assessment of Cancer Therapy—Lung; QoL, quality of life.
study design
This is a single- centre, randomised double- blind phase II 
placebo- controlled modified cross- over study. Each phase 
comprises 28- day treatment separated by a 3- day washout. 
A 2×28 day period design has been selected as it is suffi-
cient to demonstrate benefit but patient deterioration 
due to cancer progression should be modest over that 
period. The cross- over design has been selected as every 
participant will receive the intervention; this is not only 
very attractive for potential participants and their families 
(as per community feedback), but there will be reduced, 
between- patient variability, allowing greater precision 
in estimating the treatment effect. The 3- day washout 
period comprises at least 10 half- lives of the study drug, 
reducing the possibility of residual drug- effect in period 
2. The potential bias of a carry- over effect on ASM from 
periods 1 to 2 has been considered; as such, the primary 
outcome will compare ASM between the groups at end 
of period 1.
Given the expected dropout and the relatively small 
sample size, this study will adopt an adaptive- recruitment 
design that will allow further recruitment of additional 
participants in the event that withdrawal occurs in the 
period after randomisation and before baseline assess-
ment, or a participant begins period 1 but withdraws 
before day 14.
recruitment and informed consent
Potential participants will be identified through outpa-
tient clinics based at Sir Charles Gairdner Hospital, 
Perth, Western Australia. Community- based palliative 
care physicians will also be encouraged to refer poten-
tial participants. Suitable patients will be provided with 
a verbal and written explanation of the study in the 
form of an information sheet, and informed consent 
will be obtained by a member of the research team in 
accordance with good clinical practice (GCP). The inclu-
sion and exclusion criteria are listed in box 1.
randomisation and blinding
Participants will be minimised with a random element 
with a 1:1 ratio between the two groups using an online 
computer- generated randomisation sequence through 
the REDCap (REDCap V.9.3.0—2019 Vanderbilt Univer-
sity) program which will be managed by Curtin Clinical 
Trials and Data Management Centre (CCTDMC) in 
Bentley, Australia. Minimisation will be according to: 
Eastern Cooperative Oncology Group performance status 
(0–1 or 2), and histological subtype (epithelioid vs non- 
epithelioid (biphasic, sarcomatoid, not defined)). This is 
a double- blind study and assessors of outcomes will also 
be blinded; however, there will be no independent review 
of assessments.
study intervention and control arm
Patients will be randomised to receive either anamorelin 
100 mg oral tablet once daily in the first period or placebo. 
As per the cross- over design, those randomised to anamo-
relin in the first period will receive placebo in the second 
period, and vice versa. Participants will be instructed to 
take the study drug (either anamorelin or placebo) on an 
empty stomach, at approximately the same time each day 
throughout the study. Both anamorelin and the placebo 
will be packaged and labelled identically in accordance 
with GCP. All participants will receive all other appro-
priate standard care management as required.
study visit schedule
The participant visit schedule consists of face- to- face 
and telephone interactions as detailed in table 1. After 
consent, the following information will be collected from 
participants at a first face- to- face visit; demographics 
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including treatment history, medications and comorbid-
ities, histological subtype of mesothelioma; QoL ques-
tionnaires (FACT- L, ACS); blood tests (haematological, 
renal, hepatic function, blood glucose (blood sugar level 
(BSL)), ECG; objective physical functioning (repeated 
chair rise, gait speed and hand- grip strength); explora-
tory biomarkers; height; weight; vital signs; physical exam-
ination and a DXA scan. Each participant will also be 
given an accelerometer to wear for 3 days. They will also 
be contacted by a dietician to complete a 24 hours food 
recall. The participant will be instructed to commence 
taking the study drug (anamorelin or placebo) on the 
day after this visit.
At day 14 and day 46, participants from both groups 
will be contacted by telephone to ensure that they have 
performed a safety blood test to assess hepatic function 
and BSL and check on AEs or non- compliance. They will 
receive an accelerometer in the mail and be instructed to 
wear this starting 3 days prior to the next scheduled visit.
Participants will complete 28 days of treatment followed 
by a 3- day washout. At the end of both periods, participants 
will return for a face- to- face visit with further assessments 
including but not limited to: AEs or non- compliance; QoL 
questionnaires; safety blood tests; ECG; objective physical 
activity tests; exploratory biomarkers; weight and DXA scan. 
They will be contacted again by a dietician to complete a 
24 hours food recall. At the end of the first period, partici-
pants will be instructed to commence the second period of 
study drug, the day after the face- to- face assessment. After 
completion of the second period and face to face visit, 
there will be no further follow- up.
safety monitoring and reporting
There will be close monitoring for any potential AE or 
serious adverse events (SAE) from anamorelin. Participants 
may be withdrawn from the trial if they develop an AE of 
grade 3 or above or SAE related to study drug, with manda-
tory reporting to the therapeutic drugs administration as 
required. For this small study, the Data Safety Monitoring 
Board and Trial Steering Committee will be combined.
sample size
Based on previous research, an improvement in ASM 
of 0.2 kg/m2 is considered significant for patients with 
thoracic cancer taking anamorelin.17 Pilot data demon-
strate that up to 5% of the control group may have a 
0.2 kg/m2 increase in ASM adjusted for height over an 
8- week period. With 50% of the participants in the inter-
vention group expected to have a 0.2 kg/m2 increase in 
ASM adjusted for height, 15 participants per group will 
be required to detect the difference with 80% power at 
5% significance level.17 To allow for a 25% dropout rate,18 
a total sample size of 40 participants is required.
statistics
All study data will be managed by CCTDMC using a 
bespoke database created using REDCap. Confidentiality 
of participant data will be assured according to GCP. All 
participants will be included for an intention- to- treat anal-
ysis. Sensitivity analyses will be preplanned to include only 
those participants who continued study treatment for 
greater than 14 days. All participants who take one dose or 
more of study drug will be included in analyses of toxicity.
Clinical outcomes analysis
Differences between ASM (and other secondary 
endpoints) at baseline and across the follow- up time 
points will be assessed using general linear mixed effects 
model. The model will allow comparison within partici-
pants over time and between the groups, while allowing 
a time by group interaction (ie, ‘period’ and ‘interven-
tion’). Analysis for the presence of a period effect and/or 
carry- over effect will be performed with a null hypothesis 
of no difference between periods 1 and 2.
As the intervention may influence the presence (or 
absence) of missing data, we will not assume that data are 
missing at random, instead, the joint modelling approach 
detailed above will be used to assess the robustness of any 
assumptions with missing data. Survival curves of the two 
groups will be estimated using the Kaplan- Meier method 
and compared statistically using the log rank test. Covari-
ates for the mixed effects submodel will include base-
line measurements of the outcome, treatment group, 
measurements at each time point and a treatment group- 
measurement time point interaction. Sensitivity analyses 
will include physical activity and dietary intake data. 
Correlation between biomarkers of cachexia and major 
nutrients will be assessed using linear regression while 
adjusting for total energy intake.
Patient and public involvement
Our consumer reference group has been involved in the 
development of this protocol, review of patient informa-
tion consent form and the recruitment materials.
Timelines and trial status
This study plans to open to recruitment in early 2020 and 
is expected to recruit for 12–18 months.
eThICs and dIsseMInaTIon
A favourable ethical approval for this study has been 
granted by Sir Charles Gairdner Osborne Park Health 
Group Human Research Ethics Committee (Ref# 3154) 
and has been registered on Australian New Zealand Clin-
ical trials registry (U1111-1240-6828).
The study results will be disseminated via clinical and 
scientific conferences and peer- reviewed publications in 
scientific journals. A lay summary will be generated for 
patients and consumers.
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ConClusIon
Anorexia is a major symptom in MPM, and weight loss 
and cachexia are common and have prognostic impor-
tance. People with cachexia are less likely to complete 
active therapy and more likely to experience toxicities. 
Better management of anorexia may improve QoL and 
ASM. In the design of the ANTHEM study, we have 
attempted to allow as pragmatic an approach as possible, 
to ensure as wide as possible external applicability of the 
results, within the confines of ensuring internal validity 
and appropriate scientific rigour. Larger clinical trials will 
be needed to test the effects of anamorelin on survival or 
treatment toxicities and adherence.
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